Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Cohance Lifesciences's Enterprise Value is ₹164,709 Mil.
Cohance Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0 Mil. Therefore, Cohance Lifesciences's EV-to-FCF for today is .
The historical rank and industry rank for Cohance Lifesciences's EV-to-FCF or its related term are showing as below:
BOM:543064'
s EV-to-FCF Range Over the Past 10 Years
Min: 0 Med: 0 Max: 108.95
Current: 108.95
During the past 8 years, the highest EV-to-FCF of Cohance Lifesciences was 108.95. The lowest was 0.00. And the median was 0.00.
BOM:543064's EV-to-FCF is ranked worse than 87.92% of 571
companies
in the Drug Manufacturers industry
Industry Median: 20.66
vs BOM:543064: 108.95
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Cohance Lifesciences's PE Ratio (TTM) for today is calculated as:
Cohance Lifesciences's share price for today is ₹425.40.
Cohance Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹4.650.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Cohance Lifesciences EV-to-FCF Related Terms
Cohance Lifesciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Cohance Lifesciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Cohance Lifesciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cohance Lifesciences EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Cohance Lifesciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Cohance Lifesciences's EV-to-FCF falls into.
Cohance Lifesciences's current Enterprise Value is ₹164,709 Mil.
Cohance Lifesciences's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Is Cohance Lifesciences (BOM:543064) Overvalued in 2026?
Based on GuruFocus' analysis, Cohance Lifesciences stock appears to be undervalued.
The current stock price of ₹425.40 is trading 38.9% below its estimated GF Value™ of ₹695.81.
GuruFocus considers Cohance Lifesciences to be Possible Value Trap.
Key valuation signals for BOM:543064:
EV-to-FCF:
GF Value™: ₹695.81 vs. price of ₹425.40 (38.9% below fair value)
No single metric tells the full story. See the BOM:543064 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cohance Lifesciences Ltd is a CDMO and API platform, offering products and services across all phases of a molecule's lifecycle from development to commercialization. Its Business Units comprise: CDMO, API+ and Formulations, and Clinical and Analytical Services.
87GF Score
Get the complete analysis for BOM:543064
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:543064 has been successfully added to your 
